- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.03. | Mizuho bestätigt Eikon Therapeutics nach Pipeline-Update mit "Outperform" | 4 | Investing.com Deutsch | ||
| 30.03. | Mizuho reiterates Eikon Therapeutics stock rating on pipeline update | 1 | Investing.com | ||
| 30.03. | Eikon Gains on Results | - | Baystreet.ca | ||
| 30.03. | Eikon Therapeutics GAAP EPS of -$115.29 | 1 | Seeking Alpha | ||
| EIKON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 30.03. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates | 142 | GlobeNewswire (Europe) | Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4... ► Artikel lesen | |
| 30.03. | Eikon Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | Eikon Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 12.03. | Bloomberg Terminal vs. Eikon: Analyzing Financial Data Tools | 2 | Investopedia | ||
| 02.03. | Eikon Therapeutics: Aktie steigt um 6 % nach positiven Analysten-Voten | 2 | Investing.com Deutsch | ||
| 02.03. | BofA initiates Eikon Therapeutics stock with buy rating on platform potential | 3 | Investing.com | ||
| 02.03. | Mizuho initiates Eikon Therapeutics stock coverage with outperform | 2 | Investing.com | ||
| 02.03. | Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight | 4 | Investing.com | ||
| 02.03. | JPMorgan startet Coverage für Eikon Therapeutics mit "Overweight" | 2 | Investing.com Deutsch | ||
| 02.03. | Morgan Stanley sieht bei Eikon Therapeutics erhebliches Kurspotenzial | 5 | Investing.com Deutsch | ||
| 02.03. | JPMorgan initiates Eikon Therapeutics stock at Overweight | 1 | Investing.com | ||
| 26.02. | Eikon Therapeutics: Aktie fällt nach Herabstufung durch Wedbush | 4 | Investing.com Deutsch | ||
| 06.02. | Eikon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 06.02. | Eikon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.02. | Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials | 1 | MedCity News | ||
| 05.02. | Immuno-responsive cancer biotech Eikon Therapeutics prices upsized IPO at $18 high end | 1 | Renaissance Capital |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BIONTECH | 81,40 | -0,06 % | BioNTech-Wirkstoff BNT323 zeigt Wirkung bei Gebärmutterkrebs | BioNTech hat positive Daten aus einer Phase-2-Studie mit dem Antikörper-Wirkstoff-Konjugat Trastuzumab Pamirtecan (BNT323/DB-1303) veröffentlicht. In einer Kohorte mit stark vorbehandelten Patientinnen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,670 | +1,86 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| CG ONCOLOGY | 67,69 | -1,25 % | H.C. Wainwright hebt Kursziel für CG Oncology auf 100 US-Dollar an |
Das Unternehmen EIKON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 9,020 Euro und damit +0,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EIKON THERAPEUTICS INC finden Sie auf Wallstreet Online.